PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

Journal of Clinical Oncology

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

The Lancet Oncology

OncologyCancer ManagementMaintenance TherapyCancer TreatmentMedicine +3

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

William J. Gradishar, Virginia Kaklamani, Tarini Prasad Sahoo, +7

European Journal of Cancer

First-line TherapyBreast OncologyMedicinePharmacologyClinical Trials +4

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

Dae Ho Lee, Jung Shin Lee, Sang‐We Kim, +10

European Journal of Cancer

Second-line TreatmentMedicinePharmacologyClinical TrialsPharmacotherapy +5

PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

Journal of Clinical Oncology

Surgical OncologyCancer ManagementPrognosisPathologyOncology +14

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer

Susan G. Urba, Carla M.L. van Herpen, Tarini Prasad Sahoo, +11

Cancer

Synthesis of potassium-zinc hexacyanoferrate and their SPEEK composite cation exchange membranes for selective recovery of cesium from aqueous system

Jasmeetkaur C. Bassan, Prashant Upadhyay, Neeta Maheshwari, +3

Chemical Engineering Journal

Catalytic MembranePurification MethodChemical EngineeringAqueous SystemEngineering +6

New normal baseline data during nationwide lock down due to Covid 19 pandemic in the world’s largest ship recycling yard at Alang, India

Amit Chanchpara, Vasavdutta Sonpal, Gauravkumar Mehta, +4

Environmental Science and Pollution Research

PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, +14

Journal of Clinical Oncology

Disease ProgressionPrognosisPharmacotherapyAdvanced Ns NsclcLogistic Analysis +14

Physiological differentiation among nine-spined stickleback populations: Effects of copper exposure

Wolfgang Waser, Tarini Prasad Sahoo, Gábor Herczeg, +2

Aquatic Toxicology

Animal PhysiologyBiologyAnimal StudyNatural SciencesPhysiology +5